Federated Hermes
TCRR

Federated Hermes’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Federated Hermes’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,081
Closed -$10.6K – 2263
2023
Q1 		$10.6K Sell
7,081
-9,630
-58% -$13K ﹤0.01% 1871
2022
Q4 		$16.7K Buy
16,711
+1,635
+11% +$2.2K ﹤0.01% 1822
2022
Q3 		$27K Buy
15,076
+1,066
+8% +$3.09K ﹤0.01% 1745
2022
Q2 		$41K Sell
14,010
-1,697
-11% -$4.19K ﹤0.01% 1692
2022
Q1 		$43K Buy
15,707
+9,818
+167% +$30.9K ﹤0.01% 1753
2021
Q4 		$27K Buy
+5,889
New +$36.8K ﹤0.01% 1859
2021
Q2 		– Sell
-112,795
Closed -$2.49M – 2372
2021
Q1 		$2.49M Buy
112,795
+50,535
+81% +$1.38M ﹤0.01% 1036
2020
Q4 		$1.93M Buy
62,260
+61,926
+18,541% +$1.57M ﹤0.01% 1080
2020
Q3 		$7K Buy
+334
New +$5.86K ﹤0.01% 2004

Federated Hermes's TCRR Position: Q2 2023 in Review

Federated Hermes sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 7,081 shares — an estimated $10.6K sold.

Federated Hermes first reported a position in TCRR in Q3 2020 and held it in 9 quarters. The position peaked at $2.49M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

  • Federated Hermes reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Federated Hermes sold 7,081 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $10.6K.
  • Federated Hermes first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • Federated Hermes's TCR2 Therapeutics Inc. Common Stock position peaked at $2.49M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.